For research and educational purposes only. Not medical advice.

S-23 Reference

Educational, not medical advice reference for S-23: SARM; regulatory status, evidence posture, source review, and schedule notes. Also known as Non-steroidal…

Reference summary

Preclinical rat work demonstrated reversible spermatogenesis suppression in animal models. Direct human clinical efficacy data were not located during review.

Categories
SARM
Aliases
Non-steroidal SARM, Investigational male contraceptive SARM
Evidence posture
preclinical — FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 at all times. Suppresses spermatogenesis in preclinical animal models — human male-contraceptive efficacy is unproven. No FDA-approved drug label.
Regulatory status
No FDA-approved S-23 drug label. WADA prohibits SARMs under category S1.2 at all times. FDA enforcement against SARMs sellers applies. S-23 has been studied as a candidate male contraceptive in preclinical animal literature.
Content review status
research reference

Selected public sources